c. optionally, at least one linking moiety for linking said at least one albumin binding domain or derivative thereof to the C or N terminal of said at least one C5 binding polypeptide.

25. The C5 binding polypeptide according to any one of claims 1-12 or the C5 binding compound according to any one of claims 13-24 for use in therapy.

26. The C5 binding polypeptide according to any one of claims 1-12 or the C5 binding compound according to any one of claims 13-24 for use in a method for treatment and/or prophylaxis of a C5-related condition.

27. The C5 binding polypeptide for use or the C5 binding compound for use according to claim 26, wherein said C5-related condition is a condition selected from inflammatory diseases; autoimmune diseases; infectious diseases; cardiovascular diseases; neurodegenerative disorders; graft injury; eye diseases; kidney diseases; pulmonary diseases; haematological diseases such as paroxysmal nocturnal hemoglobinuria (PNH); allergic diseases and dermatological diseases.

28. The C5 binding polypeptide for use or the C5 binding compound for use according to any one of claims 25-27, wherein said C5 binding polypeptide or compound is administered intravenously, subcutaneously, by inhalation, nasally, orally, intravitreally, or topically.

c. optionally, at least one linking moiety for linking said at least one albumin binding domain or derivative thereof to the C or N terminal of said at least one C5 binding polypeptide.

25. The C5 binding polypeptide according to any one of claims 1-12 or the C5 binding compound according to any one of claims 13-24 for use in therapy.

26. The C5 binding polypeptide according to any one of claims 1-12 or the C5 binding compound according to any one of claims 13-24 for use in treatment and/or prophylaxis of a C5-related condition.

27. The C5 binding polypeptide for use or the C5 binding compound for use according to claim 26, wherein said C5-related condition is a condition selected from inflammatory diseases; autoimmune diseases; infectious diseases; cardiovascular diseases; neurodegenerative disorders; graft injury; eye diseases; kidney diseases; pulmonary diseases; haematological diseases such as paroxysmal nocturnal hemoglobinuria (PNH); allergic diseases and dermatological diseases.

28. The C5 binding polypeptide for use or the C5 binding compound for use according to any one of claims 25-27, wherein said C5 binding polypeptide or compound is administered intravenously, subcutaneously, by inhalation, nasally, orally, intravitreally, or topically.